PATH | VRL
Menu

Safety of Russian-Backbone Seasonal Trivalent, Live-Attenuated Influenza Vaccine in a Phase II Randomized Placebo-Controlled Clinical Trial Among Children in Urban Bangladesh

This article, published in Vaccine, reports the results of a study to evaluate the safety of a Russian-backbone, seasonal trivalent, live-attenuated influenza vaccine (LAIV) in children aged 24 through 59 months in Bangladesh. The authors found that the Russian-backbone LAIV was well tolerated and safe, and recommend further evaluation of the LAIV's safety and efficacy in a larger trial.

Author: Ortiz JR, Goswami D, Lewis KDC, et al.

Published: 2015

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Ortiz JR, Goswami D, Lewis KDC, et al. Safety of Russian-Backbone Seasonal Trivalent, Live-Attenuated Influenza Vaccine in a Phase II Randomized Placebo-Controlled Clinical Trial Among Children in Urban Bangladesh. Vaccine. 2015;33(29):3415-3421.

Resource types: Peer-reviewed journal

Diseases/vaccines: Influenza

Topics: Vaccine safety and performance, Disease/vaccine specific information

Regions: Asia